<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:dc="http://purl.org/dc/elements/1.1/">
<channel>
<title>心血管高分期刊</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;v=2.17.9.post6+86293ac&amp;utm_source=Chrome&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;utm_campaign=pubmed-2&amp;ff=20230824221425&amp;utm_medium=rss
    <description>心血管高分期刊: Latest results from PubMed</description>
<atom:link href="https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;v=2.17.9.post6+86293ac&amp;utm_source=Chrome&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;utm_campaign=pubmed-2&amp;ff=20230824221425&amp;utm_medium=rss" rel="self"></atom:link>
<docs>http://www.rssboard.org/rss-specification</docs>
<generator>PubMed RSS feeds (2.17.9.post6+86293ac)</generator>
<language>en</language>
<lastbuilddate>Fri, 25 Aug 2023 02:14:26 +0000</lastbuilddate>
<pubDate>Wed, 23 Aug 2023 06:00:00 -0400</pubDate>
<ttl>120</ttl>
<item>
<title>Reply: Understanding Myocardial Infarction in Young Individuals Now or in 30 Years?</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37612018/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230824221425&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2023 Aug 29;82(9):e77. doi: 10.1016/j.jacc.2023.06.018.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37612018/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230824221425&v=2.17.9.post6+86293ac">37612018</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2023.06.018>10.1016/j.jacc.2023.06.018</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37612018</guid>
<pubDate>Wed, 23 Aug 2023 06:00:00 -0400</pubDate>
<dc:creator>Jaejin An</dc:creator>
<dc:creator>Yiyi Zhang</dc:creator>
<dc:creator>Andrew E Moran</dc:creator>
<dc:creator>Kristi Reynolds</dc:creator>
<dc:date>2023-08-23</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Reply: Understanding Myocardial Infarction in Young Individuals Now or in 30 Years?</dc:title>
<dc:identifier>pmid:37612018</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2023.06.018</dc:identifier>
</item>
<item>
<title>Understanding Myocardial Infarction in Young Individuals Now or in 30 Years?</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37612017/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230824221425&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2023 Aug 29;82(9):e75-e76. doi: 10.1016/j.jacc.2023.05.068.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37612017/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230824221425&v=2.17.9.post6+86293ac">37612017</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2023.05.068>10.1016/j.jacc.2023.05.068</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37612017</guid>
<pubDate>Wed, 23 Aug 2023 06:00:00 -0400</pubDate>
<dc:creator>Michel Zeitouni</dc:creator>
<dc:creator>Johanne Silvain</dc:creator>
<dc:creator>Jean-Philippe Collet</dc:creator>
<dc:creator>Gilles Montalescot</dc:creator>
<dc:date>2023-08-23</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Understanding Myocardial Infarction in Young Individuals Now or in 30 Years?</dc:title>
<dc:identifier>pmid:37612017</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2023.05.068</dc:identifier>
</item>
<item>
<title>Correction</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37612016/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230824221425&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2023 Aug 29;82(9):969. doi: 10.1016/j.jacc.2023.07.010.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37612016/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230824221425&v=2.17.9.post6+86293ac">37612016</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2023.07.010>10.1016/j.jacc.2023.07.010</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37612016</guid>
<pubDate>Wed, 23 Aug 2023 06:00:00 -0400</pubDate>
<dc:date>2023-08-23</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Correction</dc:title>
<dc:identifier>pmid:37612016</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2023.07.010</dc:identifier>
</item>
<item>
<title>Artificial Intelligence, Bob Dylan, and Cardiovascular Scholarship</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37612015/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230824221425&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2023 Aug 29;82(9):961-963. doi: 10.1016/j.jacc.2023.07.006.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37612015/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230824221425&v=2.17.9.post6+86293ac">37612015</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2023.07.006>10.1016/j.jacc.2023.07.006</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37612015</guid>
<pubDate>Wed, 23 Aug 2023 06:00:00 -0400</pubDate>
<dc:creator>Harold L Dauerman</dc:creator>
<dc:creator>Justine Varieur Turco</dc:creator>
<dc:creator>Valentin Fuster</dc:creator>
<dc:date>2023-08-23</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Artificial Intelligence, Bob Dylan, and Cardiovascular Scholarship</dc:title>
<dc:identifier>pmid:37612015</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2023.07.006</dc:identifier>
</item>
<item>
<title>Sex Differences in Thoracic Aortic Disease and Dissection: JACC Review Topic of the Week</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37612014/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230824221425&amp;v=2.17.9.post6+86293ac
      <description>Despite its higher prevalence among men, women with thoracic aortic aneurysm and dissection (TAAD) have lower rates of treatment and surgical intervention and often have worse outcomes. A growing number of women with TAAD also desire pregnancy, which can be associated with an increased risk of aortic complications. Understanding sex-specific differences in TAAD has the potential to improve care delivery, reduce disparities in treatment, and optimize outcomes for women with TAAD.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2023 Aug 29;82(9):817-827. doi: 10.1016/j.jacc.2023.05.067.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Despite its higher prevalence among men, women with thoracic aortic aneurysm and dissection (TAAD) have lower rates of treatment and surgical intervention and often have worse outcomes. A growing number of women with TAAD also desire pregnancy, which can be associated with an increased risk of aortic complications. Understanding sex-specific differences in TAAD has the potential to improve care delivery, reduce disparities in treatment, and optimize outcomes for women with TAAD.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37612014/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230824221425&v=2.17.9.post6+86293ac">37612014</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2023.05.067>10.1016/j.jacc.2023.05.067</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37612014</guid>
<pubDate>Wed, 23 Aug 2023 06:00:00 -0400</pubDate>
<dc:creator>Daniela Crousillat</dc:creator>
<dc:creator>Joan Briller</dc:creator>
<dc:creator>Niti Aggarwal</dc:creator>
<dc:creator>Leslie Cho</dc:creator>
<dc:creator>Thais Coutinho</dc:creator>
<dc:creator>Colleen Harrington</dc:creator>
<dc:creator>Eric Isselbacher</dc:creator>
<dc:creator>Kathryn Lindley</dc:creator>
<dc:creator>Maral Ouzounian</dc:creator>
<dc:creator>Ourania Preventza</dc:creator>
<dc:creator>Jyoti Sharma</dc:creator>
<dc:creator>Ranya Sweis</dc:creator>
<dc:creator>Melissa Russo</dc:creator>
<dc:creator>Nandita Scott</dc:creator>
<dc:creator>Nupoor Narula</dc:creator>
<dc:date>2023-08-23</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Sex Differences in Thoracic Aortic Disease and Dissection: JACC Review Topic of the Week</dc:title>
<dc:identifier>pmid:37612014</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2023.05.067</dc:identifier>
</item>
<item>
<title>Congenital Heart Surgery Outcomes: Looking Beyond the Hospital Walls</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37612013/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230824221425&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2023 Aug 29;82(9):814-816. doi: 10.1016/j.jacc.2023.06.017.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37612013/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230824221425&v=2.17.9.post6+86293ac">37612013</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2023.06.017>10.1016/j.jacc.2023.06.017</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37612013</guid>
<pubDate>Wed, 23 Aug 2023 06:00:00 -0400</pubDate>
<dc:creator>Carlos M Mery</dc:creator>
<dc:creator>Andrew Well</dc:creator>
<dc:date>2023-08-23</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Congenital Heart Surgery Outcomes: Looking Beyond the Hospital Walls</dc:title>
<dc:identifier>pmid:37612013</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2023.06.017</dc:identifier>
</item>
<item>
<title>Neighborhood Childhood Opportunity, Race/Ethnicity, and Surgical Outcomes in Children With Congenital Heart Disease</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37612012/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230824221425&amp;v=2.17.9.post6+86293ac
      <description>CONCLUSIONS: Children in the lowest COI quintile are at risk for poor outcomes after CHD surgery. Disproportionally increased mortality in Black, Asian, and Other populations may be partially mediated by COI. Targeted investment in low COI neighborhoods may improve outcomes after hospital discharge. Identification of unmeasured factors to explain persistent risk attributed to race/ethnicity is an important area of future exploration.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2023 Aug 29;82(9):801-813. doi: 10.1016/j.jacc.2023.05.069.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Racial and ethnic disparities in outcomes for children with congenital heart disease (CHD) coexist with disparities in educational, environmental, and economic opportunity.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVES: We sought to determine the associations between childhood opportunity, race/ethnicity, and pediatric CHD surgery outcomes.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: Pediatric Health Information System encounters aged &lt;18 years from 2016 to 2022 with International Classification of Diseases-10th edition codes for CHD and cardiac surgery were linked to ZIP code-level Childhood Opportunity Index (COI), a score of neighborhood educational, environmental, and socioeconomic conditions. The associations of race/ethnicity and COI with in-hospital surgical death were modeled with generalized estimating equations and formal mediation analysis. Neonatal survival after discharge was modeled by Cox proportional hazards.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Of 54,666 encounters at 47 centers, non-Hispanic Black (Black) (OR: 1.20; P = 0.01), Asian (OR: 1.75; P &lt; 0.001), and Other (OR: 1.50; P &lt; 0.001) groups had increased adjusted mortality vs non-Hispanic Whites. The lowest COI quintile had increased in-hospital mortality in unadjusted and partially adjusted models (OR: 1.29; P = 0.004), but not fully adjusted models (OR: 1.14; P = 0.13). COI partially mediated the effect of race/ethnicity on in-hospital mortality between 2.6% (P = 0.64) and 16.8% (P = 0.029), depending on model specification. In neonatal multivariable survival analysis (n = 13,987; median follow-up: 0.70 years), the lowest COI quintile had poorer survival (HR: 1.21; P = 0.04).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Children in the lowest COI quintile are at risk for poor outcomes after CHD surgery. Disproportionally increased mortality in Black, Asian, and Other populations may be partially mediated by COI. Targeted investment in low COI neighborhoods may improve outcomes after hospital discharge. Identification of unmeasured factors to explain persistent risk attributed to race/ethnicity is an important area of future exploration.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37612012/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230824221425&v=2.17.9.post6+86293ac">37612012</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2023.05.069>10.1016/j.jacc.2023.05.069</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37612012</guid>
<pubDate>Wed, 23 Aug 2023 06:00:00 -0400</pubDate>
<dc:creator>Son Q Duong</dc:creator>
<dc:creator>Mahmud O Elfituri</dc:creator>
<dc:creator>Isabella Zaniletti</dc:creator>
<dc:creator>Robert W Ressler</dc:creator>
<dc:creator>Clemens Noelke</dc:creator>
<dc:creator>Bruce D Gelb</dc:creator>
<dc:creator>Robert H Pass</dc:creator>
<dc:creator>Carol R Horowitz</dc:creator>
<dc:creator>Howard S Seiden</dc:creator>
<dc:creator>Brett R Anderson</dc:creator>
<dc:date>2023-08-23</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Neighborhood Childhood Opportunity, Race/Ethnicity, and Surgical Outcomes in Children With Congenital Heart Disease</dc:title>
<dc:identifier>pmid:37612012</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2023.05.069</dc:identifier>
</item>
<item>
<title>Detecting Concealed Phase and Progression in Subclinical ARVC: Tackling the Age Spectrum Challenge</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37612011/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230824221425&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2023 Aug 29;82(9):798-800. doi: 10.1016/j.jacc.2023.06.012.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37612011/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230824221425&v=2.17.9.post6+86293ac">37612011</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2023.06.012>10.1016/j.jacc.2023.06.012</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37612011</guid>
<pubDate>Wed, 23 Aug 2023 06:00:00 -0400</pubDate>
<dc:creator>Babken Asatryan</dc:creator>
<dc:date>2023-08-23</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Detecting Concealed Phase and Progression in Subclinical ARVC: Tackling the Age Spectrum Challenge</dc:title>
<dc:identifier>pmid:37612011</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2023.06.012</dc:identifier>
</item>
<item>
<title>Monitoring of Myocardial Involvement in Early Arrhythmogenic Right Ventricular Cardiomyopathy Across the Age Spectrum</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37612010/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230824221425&amp;v=2.17.9.post6+86293ac
      <description>CONCLUSIONS: Disease progression was similar in all age groups, and sustained VA also occurred in patients aged >;50 years without overt ARVC phenotype at first evaluation. Unlike recommended by current guidelines, our study suggests that follow-up of ARVC patients and relatives should not stop at older age.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2023 Aug 29;82(9):785-797. doi: 10.1016/j.jacc.2023.05.065.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Arrhythmogenic right ventricular cardiomyopathy (ARVC) is characterized by fibrofatty replacement of primarily the right ventricular myocardium, a substrate for life-threatening ventricular arrhythmias (VAs). Repeated cardiac imaging of at-risk relatives is important for early disease detection. However, it is not known whether screening should be age-tailored.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVES: The goal of this study was to assess the need for age-tailoring of follow-up protocols in early ARVC by evaluating myocardial disease progression in different age groups.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: We divided patients with early-stage ARVC and genotype-positive relatives without overt structural disease and VA at first evaluation into 3 groups: age &lt;30 years, 30 to 50 years, and ≥50 years. Longitudinal biventricular deformation characteristics were used to monitor disease progression. To link deformation abnormalities to underlying myocardial disease substrates, Digital Twins were created using an imaging-based computational modeling framework.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: We included 313 echocardiographic assessments from 82 subjects (57% female, age 39 ± 17 years, 10% probands) during 6.7 ± 3.3 years of follow-up. Left ventricular global longitudinal strain slightly deteriorated similarly in all age groups (0.1%-point per year [95% CI: 0.05-0.15]). Disease progression in all age groups was more pronounced in the right ventricular lateral wall, expressed by worsening in longitudinal strain (0.6%-point per year [95% CI: 0.46-0.70]) and local differences in myocardial contractility, compliance, and activation delay in the Digital Twin. Six patients experienced VA during follow-up.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Disease progression was similar in all age groups, and sustained VA also occurred in patients aged >;50 years without overt ARVC phenotype at first evaluation. Unlike recommended by current guidelines, our study suggests that follow-up of ARVC patients and relatives should not stop at older age.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37612010/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230824221425&v=2.17.9.post6+86293ac">37612010</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2023.05.065>10.1016/j.jacc.2023.05.065</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37612010</guid>
<pubDate>Wed, 23 Aug 2023 06:00:00 -0400</pubDate>
<dc:creator>Feddo P Kirkels</dc:creator>
<dc:creator>Nick van Osta</dc:creator>
<dc:creator>Christine Rootwelt-Norberg</dc:creator>
<dc:creator>Monica Chivulescu</dc:creator>
<dc:creator>Tim van Loon</dc:creator>
<dc:creator>Eivind W Aabel</dc:creator>
<dc:creator>Anna I Castrini</dc:creator>
<dc:creator>Øyvind H Lie</dc:creator>
<dc:creator>Folkert W Asselbergs</dc:creator>
<dc:creator>Tammo Delhaas</dc:creator>
<dc:creator>Maarten J Cramer</dc:creator>
<dc:creator>Arco J Teske</dc:creator>
<dc:creator>Kristina H Haugaa</dc:creator>
<dc:creator>Joost Lumens</dc:creator>
<dc:date>2023-08-23</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Monitoring of Myocardial Involvement in Early Arrhythmogenic Right Ventricular Cardiomyopathy Across the Age Spectrum</dc:title>
<dc:identifier>pmid:37612010</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2023.05.065</dc:identifier>
</item>
<item>
<title>LVAD Mortality Risk: It Is Difficult to Make Predictions (But It Just Got Easier)</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37612009/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230824221425&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2023 Aug 29;82(9):782-784. doi: 10.1016/j.jacc.2023.06.013.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37612009/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230824221425&v=2.17.9.post6+86293ac">37612009</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2023.06.013>10.1016/j.jacc.2023.06.013</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37612009</guid>
<pubDate>Wed, 23 Aug 2023 06:00:00 -0400</pubDate>
<dc:creator>Joseph G Rogers</dc:creator>
<dc:date>2023-08-23</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>LVAD Mortality Risk: It Is Difficult to Make Predictions (But It Just Got Easier)</dc:title>
<dc:identifier>pmid:37612009</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2023.06.013</dc:identifier>
</item>
<item>
<title>Predictors of 5-Year Mortality in Patients Managed With a Magnetically Levitated Left Ventricular Assist Device</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37612008/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230824221425&amp;v=2.17.9.post6+86293ac
      <description>CONCLUSIONS: Long-term survival in successfully discharged HM3 LVAD recipients is largely influenced by clinical events experienced during the index surgical hospitalization in tandem with baseline factors, with mortality of &lt;50% at 5 years. In patients without identified predictors of risk, long-term 5-year mortality is low and rivals that achieved with heart transplantation, even though most were implanted with destination therapy intent. (MOMENTUM 3 IDE Clinical Study Protocol, NCT02224755;...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2023 Aug 29;82(9):771-781. doi: 10.1016/j.jacc.2023.05.066.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: In advanced heart failure patients implanted with a fully magnetically levitated HeartMate 3 (HM3, Abbott) left ventricular assist device (LVAD), it is unknown how preimplant factors and postimplant index hospitalization events influence 5-year mortality in those able to be discharged.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVES: The goal was to identify risk predictors of mortality through 5 years among HM3 LVAD recipients conditional on discharge from index hospitalization in the MOMENTUM 3 pivotal trial.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: This analysis evaluated 485 of 515 (94%) patients discharged after implantation of the HM3 LVAD. Preimplant (baseline), implant surgery, and index hospitalization characteristics were analyzed individually, and as multivariable predictors for mortality risk through 5 years.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Cumulative 5-year mortality in the cohort (median age: 62 years, 80% male, 65% White, 61% destination therapy due to transplant ineligibility) was 38%. Two preimplant characteristics (elevated blood urea nitrogen and prior coronary artery bypass graft or valve procedure) and 3 postimplant characteristics (hemocompatibility-related adverse events, ventricular arrhythmias, and estimated glomerular filtration rate &lt;60 mL/min/1.73 m<sup>2</sup> at discharge) were predictors of 5-year mortality. In 171 of 485 patients (35.3%) without any risk predictors, 5-year mortality was reduced to 22.6% (95% CI: 15.4%-32.7%). Even among those with 1 or more predictors, mortality was &lt;50% at 5 years (45.7% [95% CI: 39.0%-52.8%]).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Long-term survival in successfully discharged HM3 LVAD recipients is largely influenced by clinical events experienced during the index surgical hospitalization in tandem with baseline factors, with mortality of &lt;50% at 5 years. In patients without identified predictors of risk, long-term 5-year mortality is low and rivals that achieved with heart transplantation, even though most were implanted with destination therapy intent. (MOMENTUM 3 IDE Clinical Study Protocol, NCT02224755; MOMENTUM 3 Pivotal Cohort Extended Follow-up PAS, NCT03982979).</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37612008/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230824221425&v=2.17.9.post6+86293ac">37612008</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2023.05.066>10.1016/j.jacc.2023.05.066</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37612008</guid>
<pubDate>Wed, 23 Aug 2023 06:00:00 -0400</pubDate>
<dc:creator>Aditi Nayak</dc:creator>
<dc:creator>Shelley A Hall</dc:creator>
<dc:creator>Nir Uriel</dc:creator>
<dc:creator>Daniel J Goldstein</dc:creator>
<dc:creator>Joseph C Cleveland</dc:creator>
<dc:creator>Jennifer A Cowger</dc:creator>
<dc:creator>Christopher T Salerno</dc:creator>
<dc:creator>Yoshifumi Naka</dc:creator>
<dc:creator>Douglas Horstmanshof</dc:creator>
<dc:creator>Daniel Crandall</dc:creator>
<dc:creator>AiJia Wang</dc:creator>
<dc:creator>Mandeep R Mehra</dc:creator>
<dc:date>2023-08-23</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Predictors of 5-Year Mortality in Patients Managed With a Magnetically Levitated Left Ventricular Assist Device</dc:title>
<dc:identifier>pmid:37612008</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2023.05.066</dc:identifier>
</item>
<item>
<title>Donor-Transmitted Coronary Artery Disease: Another Avenue to Expand Heart Transplantation?</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37612007/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230824221425&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2023 Aug 29;82(9):768-770. doi: 10.1016/j.jacc.2023.07.001.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37612007/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230824221425&v=2.17.9.post6+86293ac">37612007</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2023.07.001>10.1016/j.jacc.2023.07.001</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37612007</guid>
<pubDate>Wed, 23 Aug 2023 06:00:00 -0400</pubDate>
<dc:creator>Richard Cheng</dc:creator>
<dc:creator>Babak Azarbal</dc:creator>
<dc:creator>Jason Smith</dc:creator>
<dc:date>2023-08-23</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Donor-Transmitted Coronary Artery Disease: Another Avenue to Expand Heart Transplantation?</dc:title>
<dc:identifier>pmid:37612007</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2023.07.001</dc:identifier>
</item>
<item>
<title>Prevalence, Characteristics, and Prognostic Relevance of Donor-Transmitted Coronary Artery Disease in Heart Transplant Recipients</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37612006/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230824221425&amp;v=2.17.9.post6+86293ac
      <description>CONCLUSIONS: TCAD was not associated with reduced survival in patients alive and well enough to undergo post-HT angiography within the first 3 months; however, s-TCAD patients showed increased risk of cardiovascular death and MACE.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2023 Aug 29;82(9):753-767. doi: 10.1016/j.jacc.2023.06.016.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: The reported prevalence of donor-transmitted coronary artery disease (TCAD) in heart transplantation (HT) is variable, and its prognostic impact remains unclear.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVES: The goal of this study was to characterize TCAD in a contemporary multicentric cohort and to study its prognostic relevance.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: This was a retrospective study of consecutive patients >;18 years old who underwent HT in 11 Spanish centers from 2008 to 2018. Only patients with a coronary angiography (c-angio) within the first 3 months after HT were studied. Significant TCAD (s-TCAD) was defined as any stenosis ≥50% in epicardial coronary arteries, and nonsignificant TCAD (ns-TCAD) as stenosis &lt;50%. Clinical outcomes were assessed by means of Cox regression and competing risks regression. Patients were followed-up for a median period of 6.3 years after c-angio.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: From a cohort of 1,918 patients, 937 underwent c-angio. TCAD was found in 172 patients (18.3%): s-TCAD in 65 (6.9%) and ns-TCAD in 107 (11.4%). Multivariable Cox regression analysis did not show a statistically significant association between s-TCAD and all-cause mortality (adjusted HR: 1.44; 95% CI: 0.89-2.35; P = 0.141); however, it was an independent predictor of cardiovascular mortality (adjusted HR: 2.25; 95% CI: 1.20-4.19; P = 0.011) and the combined event cardiovascular death or nonfatal MACE (adjusted HR: 2.42; 95% CI: 1.52-3.85; P &lt; 0.001). No statistically significant impact of ns-TCAD on clinical outcomes was detected. The results were similar when reassessed by means of competing risks regression.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: TCAD was not associated with reduced survival in patients alive and well enough to undergo post-HT angiography within the first 3 months; however, s-TCAD patients showed increased risk of cardiovascular death and MACE.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37612006/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230824221425&v=2.17.9.post6+86293ac">37612006</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2023.06.016>10.1016/j.jacc.2023.06.016</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37612006</guid>
<pubDate>Wed, 23 Aug 2023 06:00:00 -0400</pubDate>
<dc:creator>David Couto-Mallón</dc:creator>
<dc:creator>Luis Almenar-Bonet</dc:creator>
<dc:creator>Eduardo Barge-Caballero</dc:creator>
<dc:creator>Francisco José Hernández-Pérez</dc:creator>
<dc:creator>Juan Carlos López-Azor García</dc:creator>
<dc:creator>María Jesús Valero-Masa</dc:creator>
<dc:creator>María Ángeles Castel-Lavilla</dc:creator>
<dc:creator>Sonia Mirabet-Pérez</dc:creator>
<dc:creator>Iris Paula Garrido-Bravo</dc:creator>
<dc:creator>Carles Díez-López</dc:creator>
<dc:creator>Amador López-Granados</dc:creator>
<dc:creator>Rebeca Manrique-Antón</dc:creator>
<dc:creator>Carmen Neri Fernández-Pombo</dc:creator>
<dc:creator>Javier Muñiz</dc:creator>
<dc:creator>Maria Generosa Crespo-Leiro</dc:creator>
<dc:date>2023-08-23</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Prevalence, Characteristics, and Prognostic Relevance of Donor-Transmitted Coronary Artery Disease in Heart Transplant Recipients</dc:title>
<dc:identifier>pmid:37612006</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2023.06.016</dc:identifier>
</item>
<item>
<title>Comparison of Initial Antithrombotic Regimens after Left Atrial Appendage Occlusion: A Systematic Review and Network Meta-analysis</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37611779/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230824221425&amp;v=2.17.9.post6+86293ac
      <description>CONCLUSIONS: In this network meta-analysis comparing initial antithrombotic therapies following LAAO, monotherapy with DOAC had the highest likelihood of lower thromboembolic events and major bleeding. DAPT was associated with a lower incidence of thromboembolic events compared with SAPT and may be a preferred option in patients unable to tolerate anticoagulation.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2023 Aug 16:S0735-1097(23)06450-1. doi: 10.1016/j.jacc.2023.08.010. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: The optimal antithrombotic therapy following left atrial appendage occlusion (LAAO) in patients with nonvalvular atrial fibrillation (AF) remains uncertain.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVES: To compare the efficacy and safety of various antithrombotic strategies after LAAO.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: We searched MEDLINE, Cochrane, Embase, LILACS, and ClinicalTrials.gov databases for studies reporting outcomes after LAAO, stratified by antithrombotic therapy prescribed at postprocedural discharge. Direct oral anticoagulants (DOACs), vitamin-K antagonists (VKAs), single antiplatelet therapy (SAPT), dual antiplatelet therapy (DAPT), DOAC plus SAPT, VKA plus SAPT, and no antithrombotic therapy were analyzed. We performed a frequentist random-effects model network meta-analysis to estimate the odds ratio (OR) with 95% confidence intervals (CI) for each comparison. The P-scores provided a ranking of treatments.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Forty-one studies comprising 12,451 patients with nonvalvular AF were included. DAPT, DOAC, DOAC plus SAPT, and VKA were significantly superior to no therapy to prevent device-related thrombosis. DOAC was associated with lower all-cause mortality relative to VKA (OR 0.39; 95% CI 0.17-0.89; p=0.03). As compared with SAPT, DAPT was associated with less thromboembolic events (OR 0.50; 95% CI 0.29-0.88; p=0.02), without a difference in major bleeding. In the analysis of P-scores, DOAC monotherapy was the strategy most likely to have lower thromboembolic events and major bleeding.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: In this network meta-analysis comparing initial antithrombotic therapies following LAAO, monotherapy with DOAC had the highest likelihood of lower thromboembolic events and major bleeding. DAPT was associated with a lower incidence of thromboembolic events compared with SAPT and may be a preferred option in patients unable to tolerate anticoagulation.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37611779/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230824221425&v=2.17.9.post6+86293ac">37611779</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2023.08.010>10.1016/j.jacc.2023.08.010</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37611779</guid>
<pubDate>Wed, 23 Aug 2023 06:00:00 -0400</pubDate>
<dc:creator>Pedro E P Carvalho</dc:creator>
<dc:creator>Douglas M Gewehr</dc:creator>
<dc:creator>Isabele A Miyawaki</dc:creator>
<dc:creator>Alleh Nogueira</dc:creator>
<dc:creator>Nicole Félix</dc:creator>
<dc:creator>Philippe Garot</dc:creator>
<dc:creator>Arthur Darmon</dc:creator>
<dc:creator>Patrizio Mazzone</dc:creator>
<dc:creator>Alberto Preda</dc:creator>
<dc:creator>Bruno R Nascimento</dc:creator>
<dc:creator>Luiz F Kubrusly</dc:creator>
<dc:creator>Rhanderson Cardoso</dc:creator>
<dc:date>2023-08-23</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Comparison of Initial Antithrombotic Regimens after Left Atrial Appendage Occlusion: A Systematic Review and Network Meta-analysis</dc:title>
<dc:identifier>pmid:37611779</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2023.08.010</dc:identifier>
</item>
<item>
<title>An antibiotic from an uncultured bacterium binds to an immutable target</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37611581/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230824221425&amp;v=2.17.9.post6+86293ac
      <description>Antimicrobial resistance is a leading mortality factor worldwide. Here, we report the discovery of clovibactin, an antibiotic isolated from uncultured soil bacteria. Clovibactin efficiently kills drug-resistant Gram-positive bacterial pathogens without detectable resistance. Using biochemical assays, solid-state nuclear magnetic resonance, and atomic force microscopy, we dissect its mode of action. Clovibactin blocks cell wall synthesis by targeting pyrophosphate of multiple essential...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2023 Aug 16:S0092-8674(23)00853-X. doi: 10.1016/j.cell.2023.07.038. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Antimicrobial resistance is a leading mortality factor worldwide. Here, we report the discovery of clovibactin, an antibiotic isolated from uncultured soil bacteria. Clovibactin efficiently kills drug-resistant Gram-positive bacterial pathogens without detectable resistance. Using biochemical assays, solid-state nuclear magnetic resonance, and atomic force microscopy, we dissect its mode of action. Clovibactin blocks cell wall synthesis by targeting pyrophosphate of multiple essential peptidoglycan precursors (C<sub>55</sub>PP, lipid II, and lipid III<sub>WTA</sub>). Clovibactin uses an unusual hydrophobic interface to tightly wrap around pyrophosphate but bypasses the variable structural elements of precursors, accounting for the lack of resistance. Selective and efficient target binding is achieved by the sequestration of precursors into supramolecular fibrils that only form on bacterial membranes that contain lipid-anchored pyrophosphate groups. This potent antibiotic holds the promise of enabling the design of improved therapeutics that kill bacterial pathogens without resistance development.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37611581/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230824221425&v=2.17.9.post6+86293ac">37611581</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2023.07.038>10.1016/j.cell.2023.07.038</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37611581</guid>
<pubDate>Wed, 23 Aug 2023 06:00:00 -0400</pubDate>
<dc:creator>Rhythm Shukla</dc:creator>
<dc:creator>Aaron J Peoples</dc:creator>
<dc:creator>Kevin C Ludwig</dc:creator>
<dc:creator>Sourav Maity</dc:creator>
<dc:creator>Maik G N Derks</dc:creator>
<dc:creator>Stefania De Benedetti</dc:creator>
<dc:creator>Annika M Krueger</dc:creator>
<dc:creator>Bram J A Vermeulen</dc:creator>
<dc:creator>Theresa Harbig</dc:creator>
<dc:creator>Francesca Lavore</dc:creator>
<dc:creator>Raj Kumar</dc:creator>
<dc:creator>Rodrigo V Honorato</dc:creator>
<dc:creator>Fabian Grein</dc:creator>
<dc:creator>Kay Nieselt</dc:creator>
<dc:creator>Yangping Liu</dc:creator>
<dc:creator>Alexandre M J J Bonvin</dc:creator>
<dc:creator>Marc Baldus</dc:creator>
<dc:creator>Ulrich Kubitscheck</dc:creator>
<dc:creator>Eefjan Breukink</dc:creator>
<dc:creator>Catherine Achorn</dc:creator>
<dc:creator>Anthony Nitti</dc:creator>
<dc:creator>Christopher J Schwalen</dc:creator>
<dc:creator>Amy L Spoering</dc:creator>
<dc:creator>Losee Lucy Ling</dc:creator>
<dc:creator>Dallas Hughes</dc:creator>
<dc:creator>Moreno Lelli</dc:creator>
<dc:creator>Wouter H Roos</dc:creator>
<dc:creator>Kim Lewis</dc:creator>
<dc:creator>Tanja Schneider</dc:creator>
<dc:creator>Markus Weingarth</dc:creator>
<dc:date>2023-08-23</dc:date>
<dc:source>Cell</dc:source>
<dc:title>An antibiotic from an uncultured bacterium binds to an immutable target</dc:title>
<dc:identifier>pmid:37611581</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2023.07.038</dc:identifier>
</item>
<item>
<title>Sodium-based paracetamol: impact on blood pressure, cardiovascular events, and all-cause mortality</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37611115/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230824221425&amp;v=2.17.9.post6+86293ac
      <description>CONCLUSIONS: This study does not support previous suggestions of increased SBP and an elevated risk of cardiovascular events from short-term use of sodium bicarbonate paracetamol in routine clinical practice.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2023 Aug 23:ehad535. doi: 10.1093/eurheartj/ehad535. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND AND AIMS: Effervescent formulations of paracetamol containing sodium bicarbonate have been reported to associate with increased blood pressure and a higher risk of cardiovascular diseases and all-cause mortality. Given the major implications of these findings, the reported associations were re-examined.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: Using linked electronic health records data, a cohort of 475 442 UK individuals with at least one prescription of paracetamol, aged between 60 and 90 years, was identified. Outcomes in patients taking sodium-based paracetamol were compared with those taking non-sodium-based formulations of the same. Using a deep learning approach, associations with systolic blood pressure (SBP), major cardiovascular events (myocardial infarction, heart failure, and stroke), and all-cause mortality within 1 year after baseline were investigated.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: A total of 460 980 and 14 462 patients were identified for the non-sodium-based and sodium-based paracetamol exposure groups, respectively (mean age: 74 years; 64% women). Analysis revealed no difference in SBP [mean difference -0.04 mmHg (95% confidence interval -0.51, 0.43)] and no association with major cardiovascular events [relative risk (RR) 1.03 (0.91, 1.16)]. Sodium-based paracetamol showed a positive association with all-cause mortality [RR 1.46 (1.40, 1.52)]. However, after further accounting of other sources of residual confounding, the observed association attenuated towards the null [RR 1.08 (1.01, 1.16)]. Exploratory analyses revealed dysphagia and related conditions as major sources of uncontrolled confounding by indication for this association.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: This study does not support previous suggestions of increased SBP and an elevated risk of cardiovascular events from short-term use of sodium bicarbonate paracetamol in routine clinical practice.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37611115/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230824221425&v=2.17.9.post6+86293ac">37611115</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehad535>10.1093/eurheartj/ehad535</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37611115</guid>
<pubDate>Wed, 23 Aug 2023 06:00:00 -0400</pubDate>
<dc:creator>Shishir Rao</dc:creator>
<dc:creator>Milad Nazarzadeh</dc:creator>
<dc:creator>Dexter Canoy</dc:creator>
<dc:creator>Yikuan Li</dc:creator>
<dc:creator>Jing Huang</dc:creator>
<dc:creator>Mohammad Mamouei</dc:creator>
<dc:creator>Gholamreza Salimi-Khorshidi</dc:creator>
<dc:creator>Aletta E Schutte</dc:creator>
<dc:creator>Bruce Neal</dc:creator>
<dc:creator>George Davey Smith</dc:creator>
<dc:creator>Kazem Rahimi</dc:creator>
<dc:date>2023-08-23</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Sodium-based paracetamol: impact on blood pressure, cardiovascular events, and all-cause mortality</dc:title>
<dc:identifier>pmid:37611115</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehad535</dc:identifier>
</item>
<item>
<title>Women, lipids, and atherosclerotic cardiovascular disease: a call to action from the European Atherosclerosis Society</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37611089/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230824221425&amp;v=2.17.9.post6+86293ac
      <description>Cardiovascular disease is the leading cause of death in women and men globally, with most due to atherosclerotic cardiovascular disease (ASCVD). Despite progress during the last 30 years, ASCVD mortality is now increasing, with the fastest relative increase in middle-aged women. Missed or delayed diagnosis and undertreatment do not fully explain this burden of disease. Sex-specific factors, such as hypertensive disorders of pregnancy, premature menopause (especially primary ovarian...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2023 Aug 23:ehad472. doi: 10.1093/eurheartj/ehad472. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Cardiovascular disease is the leading cause of death in women and men globally, with most due to atherosclerotic cardiovascular disease (ASCVD). Despite progress during the last 30 years, ASCVD mortality is now increasing, with the fastest relative increase in middle-aged women. Missed or delayed diagnosis and undertreatment do not fully explain this burden of disease. Sex-specific factors, such as hypertensive disorders of pregnancy, premature menopause (especially primary ovarian insufficiency), and polycystic ovary syndrome are also relevant, with good evidence that these are associated with greater cardiovascular risk. This position statement from the European Atherosclerosis Society focuses on these factors, as well as sex-specific effects on lipids, including lipoprotein(a), over the life course in women which impact ASCVD risk. Women are also disproportionately impacted (in relative terms) by diabetes, chronic kidney disease, and auto-immune inflammatory disease. All these effects are compounded by sociocultural components related to gender. This panel stresses the need to identify and treat modifiable cardiovascular risk factors earlier in women, especially for those at risk due to sex-specific conditions, to reduce the unacceptably high burden of ASCVD in women.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37611089/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230824221425&v=2.17.9.post6+86293ac">37611089</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehad472>10.1093/eurheartj/ehad472</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37611089</guid>
<pubDate>Wed, 23 Aug 2023 06:00:00 -0400</pubDate>
<dc:creator>Jeanine E Roeters van Lennep</dc:creator>
<dc:creator>Lale S Tokgözoğlu</dc:creator>
<dc:creator>Lina Badimon</dc:creator>
<dc:creator>Sandra M Dumanski</dc:creator>
<dc:creator>Martha Gulati</dc:creator>
<dc:creator>Connie N Hess</dc:creator>
<dc:creator>Kirsten B Holven</dc:creator>
<dc:creator>Maryam Kavousi</dc:creator>
<dc:creator>Meral Kayıkçıoğlu</dc:creator>
<dc:creator>Esther Lutgens</dc:creator>
<dc:creator>Erin D Michos</dc:creator>
<dc:creator>Eva Prescott</dc:creator>
<dc:creator>Jane K Stock</dc:creator>
<dc:creator>Anne Tybjaerg-Hansen</dc:creator>
<dc:creator>Marieke J H Wermer</dc:creator>
<dc:creator>Marianne Benn</dc:creator>
<dc:date>2023-08-23</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Women, lipids, and atherosclerotic cardiovascular disease: a call to action from the European Atherosclerosis Society</dc:title>
<dc:identifier>pmid:37611089</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehad472</dc:identifier>
</item>
<item>
<title>Bicuspid aortic valve: long-term morbidity and mortality</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37611071/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230824221425&amp;v=2.17.9.post6+86293ac
      <description>CONCLUSION: The BAV condition exhibits a high lifetime morbidity burden where valvulo-aortopathy is close to unavoidable by age 90. The lifetime incidence of infective endocarditis is higher than that of aortic dissection. The most common BAV clinical presentation is the typical valvulo-aortopathy with preserved expected long-term survival, while the complex valvulo-aortopathy presentation incurs higher mortality.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2023 Aug 23:ehad477. doi: 10.1093/eurheartj/ehad477. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND AND AIMS: Bicuspid aortic valve (BAV) is the most common congenital heart anomaly. Lifetime morbidity and whether long-term survival varies according to BAV patient-sub-groups are unknown. This study aimed to assess lifetime morbidity and long-term survival in BAV patients in the community.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: The authors retrospectively identified all Olmsted County (Minnesota) residents with an echocardiographic diagnosis of BAV from 1 January 1980 to 31 December 2009, including patients with typical valvulo-aortopathy (BAV without accelerated valvulo-aortopathy or associated disorders), and those with complex valvulo-aortopathy (BAV with accelerated valvulo-aortopathy or associated disorders).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: 652 consecutive diagnosed BAV patients [median (IQR) age 37 (22-53) years; 525 (81%) adult and 127 (19%) paediatric] were followed for a median (IQR) of 19.1 (12.9-25.8) years. The total cumulative lifetime morbidity burden (from birth to age 90) was 86% (95% CI 82.5-89.7); cumulative lifetime progression to ≥ moderate aortic stenosis or regurgitation, aortic valve surgery, aortic aneurysm ≥45 mm or z-score ≥3, aorta surgery, infective endocarditis and aortic dissection was 80.3%, 68.5%, 75.4%, 27%, 6% and 1.6%, respectively. Survival of patients with typical valvulo-aortopathy [562 (86%), age 40 (28-55) years, 86% adults] was similar to age-sex-matched Minnesota population (P = .12). Conversely, survival of patients with complex valvulo-aortopathy [90 (14%), age 14 (3-26) years, 57% paediatric] was lower than expected, with a relative excess mortality risk of 2.25 (95% CI 1.21-4.19) (P = .01).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSION: The BAV condition exhibits a high lifetime morbidity burden where valvulo-aortopathy is close to unavoidable by age 90. The lifetime incidence of infective endocarditis is higher than that of aortic dissection. The most common BAV clinical presentation is the typical valvulo-aortopathy with preserved expected long-term survival, while the complex valvulo-aortopathy presentation incurs higher mortality.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37611071/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230824221425&v=2.17.9.post6+86293ac">37611071</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehad477>10.1093/eurheartj/ehad477</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37611071</guid>
<pubDate>Wed, 23 Aug 2023 06:00:00 -0400</pubDate>
<dc:creator>Li-Tan Yang</dc:creator>
<dc:creator>Zi Ye</dc:creator>
<dc:creator>Muhammad Wajih Ullah</dc:creator>
<dc:creator>Joseph J Maleszewski</dc:creator>
<dc:creator>Christopher G Scott</dc:creator>
<dc:creator>Ratnasari Padang</dc:creator>
<dc:creator>Sorin V Pislaru</dc:creator>
<dc:creator>Vuyisile T Nkomo</dc:creator>
<dc:creator>Sunil V Mankad</dc:creator>
<dc:creator>Patricia A Pellikka</dc:creator>
<dc:creator>Jae K Oh</dc:creator>
<dc:creator>Veronique L Roger</dc:creator>
<dc:creator>Maurice Enriquez-Sarano</dc:creator>
<dc:creator>Hector I Michelena</dc:creator>
<dc:date>2023-08-23</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Bicuspid aortic valve: long-term morbidity and mortality</dc:title>
<dc:identifier>pmid:37611071</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehad477</dc:identifier>
</item>
<item>
<title>Diabetocardiology: a new subspecialty?</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37611068/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230824221425&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2023 Aug 23:ehad541. doi: 10.1093/eurheartj/ehad541. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37611068/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230824221425&v=2.17.9.post6+86293ac">37611068</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehad541>10.1093/eurheartj/ehad541</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37611068</guid>
<pubDate>Wed, 23 Aug 2023 06:00:00 -0400</pubDate>
<dc:creator>Eugene Braunwald</dc:creator>
<dc:date>2023-08-23</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Diabetocardiology: a new subspecialty?</dc:title>
<dc:identifier>pmid:37611068</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehad541</dc:identifier>
</item>
<item>
<title>Sodium-glucose co-transporter 2 inhibitors and mineralocorticoid receptor antagonists synergism in heart failure: it takes two to tango</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37611060/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230824221425&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2023 Aug 23:ehad540. doi: 10.1093/eurheartj/ehad540. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37611060/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230824221425&v=2.17.9.post6+86293ac">37611060</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehad540>10.1093/eurheartj/ehad540</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37611060</guid>
<pubDate>Wed, 23 Aug 2023 06:00:00 -0400</pubDate>
<dc:creator>Johann Bauersachs</dc:creator>
<dc:creator>Samira Soltani</dc:creator>
<dc:date>2023-08-23</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Sodium-glucose co-transporter 2 inhibitors and mineralocorticoid receptor antagonists synergism in heart failure: it takes two to tango</dc:title>
<dc:identifier>pmid:37611060</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehad540</dc:identifier>
</item>
<item>
<title>Severe aortic stenosis detection by deep learning applied to echocardiography</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37611002/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230824221425&amp;v=2.17.9.post6+86293ac
      <description>CONCLUSION: This study developed and externally validated an automated approach for severe AS detection using single-view 2D echocardiography, with potential utility for point-of-care screening.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2023 Aug 23:ehad456. doi: 10.1093/eurheartj/ehad456. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND AND AIMS: Early diagnosis of aortic stenosis (AS) is critical to prevent morbidity and mortality but requires skilled examination with Doppler imaging. This study reports the development and validation of a novel deep learning model that relies on two-dimensional (2D) parasternal long axis videos from transthoracic echocardiography without Doppler imaging to identify severe AS, suitable for point-of-care ultrasonography.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS AND RESULTS: In a training set of 5257 studies (17 570 videos) from 2016 to 2020 [Yale-New Haven Hospital (YNHH), Connecticut], an ensemble of three-dimensional convolutional neural networks was developed to detect severe AS, leveraging self-supervised contrastive pretraining for label-efficient model development. This deep learning model was validated in a temporally distinct set of 2040 consecutive studies from 2021 from YNHH as well as two geographically distinct cohorts of 4226 and 3072 studies, from California and other hospitals in New England, respectively. The deep learning model achieved an area under the receiver operating characteristic curve (AUROC) of 0.978 (95% CI: 0.966, 0.988) for detecting severe AS in the temporally distinct test set, maintaining its diagnostic performance in geographically distinct cohorts [0.952 AUROC (95% CI: 0.941, 0.963) in California and 0.942 AUROC (95% CI: 0.909, 0.966) in New England]. The model was interpretable with saliency maps identifying the aortic valve, mitral annulus, and left atrium as the predictive regions. Among non-severe AS cases, predicted probabilities were associated with worse quantitative metrics of AS suggesting an association with various stages of AS severity.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSION: This study developed and externally validated an automated approach for severe AS detection using single-view 2D echocardiography, with potential utility for point-of-care screening.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37611002/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230824221425&v=2.17.9.post6+86293ac">37611002</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehad456>10.1093/eurheartj/ehad456</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37611002</guid>
<pubDate>Wed, 23 Aug 2023 06:00:00 -0400</pubDate>
<dc:creator>Gregory Holste</dc:creator>
<dc:creator>Evangelos K Oikonomou</dc:creator>
<dc:creator>Bobak J Mortazavi</dc:creator>
<dc:creator>Andreas Coppi</dc:creator>
<dc:creator>Kamil F Faridi</dc:creator>
<dc:creator>Edward J Miller</dc:creator>
<dc:creator>John K Forrest</dc:creator>
<dc:creator>Robert L McNamara</dc:creator>
<dc:creator>Lucila Ohno-Machado</dc:creator>
<dc:creator>Neal Yuan</dc:creator>
<dc:creator>Aakriti Gupta</dc:creator>
<dc:creator>David Ouyang</dc:creator>
<dc:creator>Harlan M Krumholz</dc:creator>
<dc:creator>Zhangyang Wang</dc:creator>
<dc:creator>Rohan Khera</dc:creator>
<dc:date>2023-08-23</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Severe aortic stenosis detection by deep learning applied to echocardiography</dc:title>
<dc:identifier>pmid:37611002</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehad456</dc:identifier>
</item>





























</channel>
</rss>